image
Healthcare - Biotechnology - NASDAQ - US
$ 29.31
-10 %
$ 2.78 B
Market Cap
-11.87
P/E
1. INTRINSIC VALUE

This DCF valuation model was last updated on May, 7, 2025.

The intrinsic value of one SRRK stock under the worst case scenario is HIDDEN Compared to the current market price of 29.3 USD, Scholar Rock Holding Corporation is HIDDEN

This DCF valuation model was last updated on May, 7, 2025.

The intrinsic value of one SRRK stock under the base case scenario is HIDDEN Compared to the current market price of 29.3 USD, Scholar Rock Holding Corporation is HIDDEN

This DCF valuation model was last updated on May, 7, 2025.

The intrinsic value of one SRRK stock under the best case scenario is HIDDEN Compared to the current market price of 29.3 USD, Scholar Rock Holding Corporation is HIDDEN

2. FUNDAMENTAL ANALYSIS

Price Chart SRRK

image
$50.0$50.0$45.0$45.0$40.0$40.0$35.0$35.0$30.0$30.0$25.0$25.0$20.0$20.015 Nov15 NovDec '24Dec '2415 Dec15 DecJan '25Jan '2515 Jan15 JanFeb '25Feb '2515 Feb15 FebMar '25Mar '2515 Mar15 MarApr '25Apr '2515 Apr15 AprMay '25May '25
FINANCIALS
0 REVENUE
0.00%
-252 M OPERATING INCOME
-47.15%
-246 M NET INCOME
-48.56%
-201 M OPERATING CASH FLOW
-38.37%
-76.1 M INVESTING CASH FLOW
-184.87%
353 M FINANCING CASH FLOW
244.17%
0 REVENUE
0.00%
-69.4 M OPERATING INCOME
-7.07%
-66.5 M NET INCOME
-3.06%
-49.5 M OPERATING CASH FLOW
5.61%
-195 M INVESTING CASH FLOW
-553.33%
346 M FINANCING CASH FLOW
208556.63%
Balance Sheet Scholar Rock Holding Corporation
image
Current Assets 451 M
Cash & Short-Term Investments 437 M
Receivables 2.15 M
Other Current Assets 11.7 M
Non-Current Assets 23.8 M
Long-Term Investments 0
PP&E 18.4 M
Other Non-Current Assets 5.35 M
92.07 %3.88 %Total Assets$474.9m
Current Liabilities 46.9 M
Accounts Payable 10.1 M
Short-Term Debt 5.77 M
Other Current Liabilities 31.1 M
Non-Current Liabilities 59.4 M
Long-Term Debt 50.1 M
Other Non-Current Liabilities 9.21 M
9.50 %5.43 %29.23 %47.18 %8.66 %Total Liabilities$106.3m
EFFICIENCY
Earnings Waterfall Scholar Rock Holding Corporation
image
Revenue 0
Cost Of Revenue 0
Gross Profit 0
Operating Expenses 252 M
Operating Income -252 M
Other Expenses -5.76 M
Net Income -246 M
00(50m)(50m)(100m)(100m)(150m)(150m)(200m)(200m)(250m)(250m)(300m)(300m)000(252m)(252m)6m(246m)RevenueRevenueCost Of RevenueCost Of RevenueGross ProfitGross ProfitOperating ExpensesOperating ExpensesOperating IncomeOperating IncomeOther ExpensesOther ExpensesNet IncomeNet Income
RATIOS
0.00% GROSS MARGIN
0.00%
0.00% OPERATING MARGIN
0.00%
0.00% NET MARGIN
0.00%
-66.81% ROE
-66.81%
-51.86% ROA
-51.86%
-58.11% ROIC
-58.11%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis Scholar Rock Holding Corporation
image
50m50m00(50m)(50m)(100m)(100m)(150m)(150m)(200m)(200m)(250m)(250m)201720172018201820192019202020202021202120222022202320232024202420252025
Net Income -246 M
Depreciation & Amortization 1.94 M
Capital Expenditures -98 K
Stock-Based Compensation 36.6 M
Change in Working Capital 6.59 M
Others 150 K
Free Cash Flow -201 M
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets Scholar Rock Holding Corporation
image
Wall Street analysts predict an average 1-year price target for SRRK of $34.5 , with forecasts ranging from a low of $28 to a high of $42 .
SRRK Lowest Price Target Wall Street Target
28 USD -4.47%
SRRK Average Price Target Wall Street Target
34.5 USD 17.71%
SRRK Highest Price Target Wall Street Target
42 USD 43.30%
Price
Max Price Target
Min Price Target
Average Price Target
50504545404035353030252520201515101055Jun '24Jun '24Jul '24Jul '24Aug '24Aug '24Oct '24Oct '24Nov '24Nov '2420252025Feb '25Feb '25Apr '25Apr '25Jun '25Jun '25Jul '25Jul '25Aug '25Aug '25Oct '25Oct '25Nov '25Nov '2520262026Feb '26Feb '26Apr '26Apr '26
4. DIVIDEND ANALYSIS
5. COMPETITION
slide 2 of 19
6. Ownership
Insider Ownership Scholar Rock Holding Corporation
image
Sold
0-3 MONTHS
10 M USD 8
3-6 MONTHS
85.7 M USD 8
6-9 MONTHS
45 M USD 6
9-12 MONTHS
187 K USD 4
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
Scholar Rock to Host Conference Call to Discuss First Quarter 2025 Financial Results and Provide Business Update on May 14, 2025 CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK), a late-stage biopharmaceutical company focused on advancing innovative treatments for neuromuscular diseases, cardiometabolic disorders, and other serious diseases, today announced that management will host a conference call to discuss its first quarter 2025 financial results and provide a business update on Wednesday, May 14, 2025, at 8:15am ET. To access the live conference call, participants may register here. The live audio web. businesswire.com - 1 week ago
Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK; the “Company”), a late-stage biopharmaceutical company focused on advancing innovative treatments for neuromuscular diseases, cardiometabolic disorders, and other serious diseases, today announced that the company granted inducement equity awards to R. Keith Woods, its newly named Chief Operating Officer and Vikas Sinha, its newly named Chief Financial Officer, covering an aggregate of up to 1,420,134 shares of its common stock, con. businesswire.com - 1 week ago
Why Scholar Rock Stock Took a Knock on Monday Although there are many examples throughout history of positive changes in top company management teams, important personnel moves tend to unsettle investors. They get worried that significant changes could reflect instability, indecision, or both in a company's decision-making. fool.com - 3 weeks ago
Scholar Rock Appoints David L. Hallal as Chief Executive Officer; Also Announces Addition of Three Key Leaders to Scale for Next Phase of Growth CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK), a late-stage biopharmaceutical company focused on advancing innovative treatments for neuromuscular diseases, cardiometabolic disorders, and other serious diseases, announced today that David Hallal has been appointed Chief Executive Officer succeeding Jay Backstrom, M.D. David Hallal has served as Chairman of the Board at Scholar Rock since 2017 and just prior to that spent more than a decade as CEO, COO, and CCO of Alexion buildi. businesswire.com - 3 weeks ago
Why Scholar Rock Holding Stock Topped the Market Today Biotech stock Scholar Rock (SRRK 2.97%) was popular among investors on Wednesday after a positive new analyst note on the company made the rounds. This resulted in the stock bumping nearly 3% higher on the day. fool.com - 3 weeks ago
Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK; the “Company”), a late-stage biopharmaceutical company focused on advancing innovative treatments for neuromuscular diseases, cardiometabolic disorders, and other serious diseases, today announced that the company granted inducement equity awards covering an aggregate of 156,650 shares of its common stock to 19 newly hired employees, consisting of inducement stock options to purchase an aggregate of 89,515 shares of common stock and. businesswire.com - 1 month ago
FDA Grants Priority Review for Biologics License Application (BLA) and EMA Accepts Marketing Authorisation Application (MAA) for Apitegromab as a Treatment for Spinal Muscular Atrophy CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK), a late-stage biopharmaceutical company focused on advancing innovative treatments for neuromuscular diseases, cardiometabolic disorders, and other serious diseases, today announced that the U.S. Food and Drug Administration (FDA) has accepted its Biologics License Application (BLA) for apitegromab, an investigational muscle-targeted treatment that is being developed to provide clinically meaningful improvement in motor function for. businesswire.com - 1 month ago
Scholar Rock Stock Jumps On Additional Data From Pivotal Trial Of Muscular Dystrophy Treatment Scholar Rock Holding Corp. SRRK said on Sunday the company will present new efficacy and safety data from the Phase 3 pivotal SAPPHIRE trial at the 2025 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference. benzinga.com - 2 months ago
Scholar Rock Presents New Phase 3 SAPPHIRE Data at the 2025 Muscular Dystrophy Association Clinical & Scientific Conference CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK), a late-stage biopharmaceutical company focused on advancing innovative treatments for neuromuscular diseases, cardiometabolic disorders, and other serious diseases where protein growth factors play a fundamental role, today announced that new efficacy and safety data from the Phase 3 pivotal SAPPHIRE trial (NCT05156320) will be presented in multiple clinical presentations at the 2025 Muscular Dystrophy Association (MDA) Clinical &a. businesswire.com - 2 months ago
Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK; the “Company”), a late-stage biopharmaceutical company focused on advancing innovative treatments for spinal muscular atrophy, cardiometabolic disorders, and other serious diseases where protein growth factors play a fundamental role, today announced that the company granted inducement equity awards covering an aggregate of 113,800 shares of its common stock to seven newly hired employees, consisting of inducement stock options to p. businesswire.com - 2 months ago
Scholar Rock Holding Corporation (SRRK) Q4 2024 Earnings Call Transcript Scholar Rock Holding Corporation. (NASDAQ:SRRK ) Q4 2024 Earnings Conference Call February 27, 2025 8:15 AM ET Company Participants Jay Backstrom - President & CEO Ted Myles - COO & CFO Tracey Sacco - Chief Commercial Officer Conference Call Participants Allison Bratzel - Piper Sandler Michael Yee - Jefferies Tessa Romero - JPMorgan Gary Nachman - Raymond James Operator Good morning and welcome to Scholar Rock's Fourth Quarter Financial Results and Business Update Call. seekingalpha.com - 2 months ago
Scholar Rock to Present Additional Clinical Data from the Phase 3 SAPPHIRE Trial at the 2025 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK), a late-stage biopharmaceutical company focused on advancing innovative treatments for spinal muscular atrophy (SMA), cardiometabolic disorders, and other serious diseases where protein growth factors play a fundamental role, announced today that it will present additional data from its Phase 3 SAPPHIRE clinical trial (NCT05156320) at the 2025 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference being held March. businesswire.com - 2 months ago
8. Profile Summary

Scholar Rock Holding Corporation SRRK

image
COUNTRY US
INDUSTRY Biotechnology
MARKET CAP $ 2.78 B
Dividend Yield 0.00%
Description Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery and development of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of latent myostatin that has completed the Phase 3 clinical trials for the treatment of spinal muscular atrophy; and SRK-181, which is in Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies. It is also developing a pipeline of novel product candidates with potential to transform the lives of patients suffering from a range of serious diseases, including neuromuscular disorders, cancer, and fibrosis. The company has a collaboration agreement with Gilead Sciences, Inc. to discover and develop specific inhibitors of transforming growth factor beta activation for the treatment of fibrotic diseases. Scholar Rock Holding Corporation was founded in 2012 and is headquartered in Cambridge, Massachusetts.
Contact 301 Binney Street, Cambridge, MA, 02142 https://scholarrock.com
IPO Date May 25, 2018
Employees 128
Officers Dr. Jing L. Marantz M.B.A., M.D., Ph.D. Chief Medical Officer Mr. Vikas Sinha C.A., CPA, M.B.A. Chief Financial Officer Mr. Robert Keith Woods Chief Operating Officer Mr. David L. Hallal Chief Executive Officer & Chairman of the Board Mr. Edward H. Myles MBA Senior Advisor Ms. Caryn Parlavecchio Chief Human Resources Officer Mr. Mo Qatanani Ph.D. Chief Scientific Officer Dr. Akshay K. Vaishnaw M.D., Ph.D. President of R&D, Member of Scientific Advisory Board and Director Ms. Rushmie Nofsinger Vice President of Corporate Affairs & Investor Relations Ms. Junlin Ho J.D. General Counsel & Corporate Secretary